Wall Street brokerages expect Epizyme (NASDAQ:EPZM) to post earnings of ($0.54) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Epizyme’s earnings. The highest EPS estimate is ($0.52) and the lowest is ($0.56). Epizyme reported earnings per share of ($0.56) in the same quarter last year, which indicates a positive year over year growth rate of 3.6%. The business is scheduled to announce its next earnings results on Monday, May 14th.
On average, analysts expect that Epizyme will report full-year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($2.02). For the next financial year, analysts forecast that the company will post earnings of ($2.42) per share, with EPS estimates ranging from ($3.22) to ($0.87). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Epizyme.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.05. The firm’s revenue was down 100.0% compared to the same quarter last year.
Shares of NASDAQ:EPZM traded down $1.50 on Thursday, hitting $14.85. The company’s stock had a trading volume of 514,308 shares, compared to its average volume of 442,865. Epizyme has a 12 month low of $9.30 and a 12 month high of $21.40. The stock has a market cap of $1,031.18, a price-to-earnings ratio of -6.81 and a beta of 1.96.
In other news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now owns 74,867 shares in the company, valued at $1,245,038.21. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 25.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. TIAA CREF Investment Management LLC lifted its holdings in shares of Epizyme by 2.6% in the fourth quarter. TIAA CREF Investment Management LLC now owns 112,844 shares of the biopharmaceutical company’s stock valued at $1,416,000 after buying an additional 2,832 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Epizyme by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 202,178 shares of the biopharmaceutical company’s stock valued at $3,852,000 after buying an additional 5,140 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Epizyme by 12.6% in the third quarter. New York State Common Retirement Fund now owns 46,600 shares of the biopharmaceutical company’s stock valued at $888,000 after buying an additional 5,200 shares during the period. American International Group Inc. lifted its holdings in shares of Epizyme by 19.3% in the fourth quarter. American International Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 5,334 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Epizyme by 17.3% in the third quarter. Wells Fargo & Company MN now owns 36,473 shares of the biopharmaceutical company’s stock valued at $695,000 after buying an additional 5,376 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Epizyme (EPZM) Expected to Post Earnings of -$0.54 Per Share” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3341017/epizyme-epzm-expected-to-post-earnings-of-0-54-per-share.html.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.